Maze Therapeutics (NASDAQ:MAZE) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners began coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $28.00 price target on the stock. Leerink Partners’ price objective indicates a potential upside of 158.78% from the stock’s previous close.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $10.82 on Tuesday. Maze Therapeutics has a 12 month low of $10.66 and a 12 month high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.